Mechanism of Action of the LAT1 Inhibitor Being Developed by Our Company
NEWS
-
- 2026.10.09
-
J-Pharma Holds Investigator Meeting to Prepare for Expansion of the Global Phase III Beacon-BTC Study of Nanvuranlat to Japan －Study Plan Shared with Prospective Investigators to Support the Conduct of the Study in Japan－
-
- 2026.10.07
-
J-Pharma President and CEO Masuhiro Yoshitake Speaks at BioJapan 2026 Luncheon Seminar － Seminar Title: Real-World Lessons in Global Clinical Development and Market Expansion －
-
- 2026.10.05
-
“J-Pharma Selected for Funding under AMED’s Global Research and Development Support Project for the Treatment of Intractable/Rare Diseases”
